Cantor Fitzgerald Comments on GPCR FY2025 Earnings

Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Structure Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will post earnings per share of ($1.09) for the year. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share.

GPCR has been the topic of a number of other reports. HC Wainwright cut their price target on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Citigroup assumed coverage on Structure Therapeutics in a research note on Friday, May 2nd. They issued a "buy" rating and a $60.00 price target on the stock. Finally, William Blair assumed coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an "outperform" rating on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $76.50.

Structure Therapeutics Stock Down 2.4%

Structure Therapeutics stock traded down $0.54 during midday trading on Tuesday, reaching $21.68. The company's stock had a trading volume of 669,777 shares, compared to its average volume of 855,332. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $52.14. The company has a market cap of $1.24 billion, a P/E ratio of -29.30 and a beta of -1.87. The business has a 50-day simple moving average of $22.64 and a 200-day simple moving average of $24.68.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03).

Hedge Funds Weigh In On Structure Therapeutics

Hedge funds have recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd grew its holdings in shares of Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after purchasing an additional 553 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Structure Therapeutics during the fourth quarter worth about $34,000. National Bank of Canada FI grew its holdings in shares of Structure Therapeutics by 1,448.2% during the first quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock worth $51,000 after purchasing an additional 2,766 shares during the last quarter. Virtus ETF Advisers LLC grew its holdings in shares of Structure Therapeutics by 25.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after purchasing an additional 455 shares during the last quarter. Finally, Assetmark Inc. grew its holdings in shares of Structure Therapeutics by 72.3% during the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after buying an additional 953 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.